A hormone released during exercise shields nerve cells from MS damage
For years, clinicians have observed that movement seems to slow the march of multiple sclerosis, yet the reason remained elusive. A study published in Nature now offers a molecular candidate: irisin, a hormone the muscles release during exercise, appears to cross into the brain and shield nerve cells from the inflammatory damage that defines MS. The discovery bridges exercise physiology and neurology in a way that reframes physical activity not merely as lifestyle advice, but as a potential source of therapeutic molecules — a reminder that the body's own chemistry may hold answers medicine has long been seeking elsewhere.
- Multiple sclerosis affects nearly 3 million people worldwide, and current treatments rely heavily on immunosuppressive drugs that carry significant risks — leaving patients and researchers hungry for gentler, more targeted options.
- The hormone irisin, produced by muscles during movement, was found to reduce inflammatory nerve damage and preserve neural structure in MS mouse models, offering a concrete biological explanation for exercise's long-observed protective effect.
- This finding collides two fields that rarely spoke to each other — exercise physiology and neurodegenerative disease treatment — forcing a rethink of whether the benefits of physical activity are partly hormonal rather than purely mechanical.
- The critical uncertainty now is translation: irisin must be shown to cross the human blood-brain barrier as effectively as it does in rodents, and clinical trials must confirm it can slow progression or reduce relapses in actual patients.
- If human trials succeed, treatment could evolve toward combination strategies — natural irisin boosted through exercise, supplemented by pharmaceutical irisin or mimicking compounds for those who cannot exercise or need greater protection.
Scientists have long suspected that exercise benefits people with multiple sclerosis beyond simple fitness, but the biological mechanism stayed frustratingly out of reach. Research now published in Nature points to a specific answer: irisin, a hormone released by muscles during physical activity, appears to protect neurons from the damage MS inflicts.
Irisin travels through the bloodstream and crosses into the brain, where it seems to trigger protective responses in nerve cells. In mouse models of MS, it reduced the inflammatory damage characteristic of the disease and helped preserve the structural integrity of neurons — the very fibers whose insulating myelin sheath MS systematically destroys.
What gives the finding its weight is that it explains something clinicians have quietly noted for years: patients who exercise regularly tend to experience slower disease progression and better quality of life. Irisin appears to be one of the hormonal messengers through which movement earns that protective effect, drawing exercise physiology and neurodegenerative research into unexpected conversation.
The road from mouse model to human therapy is long. Researchers must confirm that irisin crosses the blood-brain barrier as reliably in humans, produces comparable neuroprotective effects, and can be safely administered at therapeutic doses. Clinical trials will need to show measurable impact on progression, relapse rates, or neurological function.
Should those trials succeed, treatment strategies could expand meaningfully — exercise to raise natural irisin levels, paired with pharmaceutical irisin or irisin-mimicking compounds for patients who cannot exercise or require additional protection. For now, the finding reinforces existing guidance that people with MS should move as much as their condition permits, while quietly opening a new front in the search for therapies against a disease that touches millions of lives.
Scientists have long known that exercise helps people with multiple sclerosis manage their symptoms, but the mechanism behind that benefit has remained largely mysterious. New research published in Nature suggests a concrete answer: a hormone called irisin, released naturally during physical activity, appears to shield nerve cells from the damage that MS inflicts.
Irisin is produced by muscles when the body moves. It circulates through the bloodstream and crosses into the brain, where it seems to trigger protective responses in neurons. In mouse models of MS, researchers found that irisin reduced the inflammatory damage characteristic of the disease and helped preserve the structural integrity of nerve cells. The finding is significant because MS is a progressive neurological condition in which the immune system attacks the myelin sheath that insulates nerve fibers, leading to communication breakdowns between the brain and body.
What makes this discovery particularly compelling is that it offers a biological explanation for something clinicians have observed for years: patients who exercise regularly tend to experience slower disease progression and better quality of life than sedentary patients. The hormone appears to be one of the mechanisms through which movement confers its protective effect. This bridges two traditionally separate fields—exercise physiology and neurodegenerative disease treatment—and suggests that the benefits of physical activity may be partly hormonal rather than purely mechanical or psychological.
The research was conducted in animal models, which means the next critical step is determining whether irisin works the same way in human brains. If it does, the implications could reshape how MS is treated. Rather than relying solely on immunosuppressive drugs that carry their own risks, clinicians might eventually prescribe irisin-based therapies or develop compounds that enhance the body's natural production of the hormone. Some patients might benefit from a combination approach: exercise to boost natural irisin levels, supplemented by pharmaceutical irisin or irisin-mimicking drugs for those unable to exercise or needing additional protection.
The path from mouse model to human treatment is long and uncertain. Researchers will need to confirm that irisin crosses the blood-brain barrier as effectively in humans as it appears to in rodents, that it produces similar neuroprotective effects, and that it can be safely administered or stimulated at therapeutic doses. Clinical trials will be required to measure whether irisin-based interventions actually slow MS progression, reduce relapse rates, or improve neurological function in patients.
For now, the finding reinforces what neurologists already recommend: people with MS should exercise as much as their condition allows. But it also opens a new research direction. If irisin proves effective in human trials, it could become part of the therapeutic arsenal against a disease that affects nearly 3 million people worldwide. The hormone may not be a cure, but it could be one more tool to help the nervous system resist the damage MS causes.
Citas Notables
The research suggests that exercise benefits in MS may be partly hormonal rather than purely mechanical or psychological— Study findings in Nature
La Conversación del Hearth Otra perspectiva de la historia
So irisin is just a hormone your muscles make when you move. Why would that matter for a brain disease?
Because MS is fundamentally about inflammation and nerve damage in the brain. If irisin can cross into the brain and calm that inflammation, it's not just a fitness benefit—it's a drug candidate.
But you tested this in mice, not people. How confident are you that it will work the same way in a human brain?
That's the honest answer: we don't know yet. Mouse brains are simpler. Human brains are bigger, more complex, and the blood-brain barrier is more selective. We need human trials.
If it does work, what would treatment look like? Would people just exercise more?
Some might. But for patients who can't exercise due to disability, or who need more protection than exercise alone provides, we'd develop irisin as a drug—either the hormone itself or a compound that mimics it.
How long until we know if this actually helps MS patients?
Clinical trials typically take years. We're probably looking at five to ten years before we'd have solid evidence one way or another. But the basic science is promising enough to justify the investment.